FOLH1 and metastatic neoplasm: Per 1000 patients with BCR (assumed median age, 66 years), upfront PSMA-PET alone (strategy 1) was estimated to detect 611 patients (95% uncertainty interval [UI], 565-656 patients) with metastatic disease, 140 patients (95% UI, 109-177 patients) with localized disease, and 249 patients (95% UI, 212-290 patients) with no radiographic disease.